Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$35.84

1.41 (4.10%)

17:03
05/18/17
05/18
17:03
05/18/17
17:03

Piper sees limited impact on Sarepta sales from FDA vote

Piper Jaffray analyst Edward Tenthoff sees a limited impact on sales from the FDA's unanimous vote allowing the use of central venous catheters to administer exon skipping drugs SRP-4045 and SRP-4053 in the Phase III ESSENCE trial. The use of IV ports will benefit DMD boys experiencing pain and trauma related to intravenous injection, and potentially lower discontinuation rates, but not impact Exondys51 sales in the near-term, Tenthoff tells investors in a research note. He keeps an Overweight rating on Sarepta Therapeutics with a $43 price target.

SRPT Sarepta
$35.84

1.41 (4.10%)

04/24/17
PIPR
04/24/17
NO CHANGE
Target $43
PIPR
Overweight
Sarepta drugs get FDA panel in May, says Piper Jaffray
Sarepta Therapeutics announced the FDA's Pediatric Advisory Committee and the Pediatric Ethics Subcommittee will meet on May 18 to discuss a referral by an Institutional Review Board of the Phase III Essence study evaluating exon skipping drugs SRP-4045 and SRP-4053, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. As planned, when 75 DMD boys aged 7-13 years had been enrolled for 48 weeks, an IRB would review to determine any protocol modifications to progress to 96 weeks of treatment, the analyst adds. He maintains an Overweight rating on Sarepta with a $43 price target ahead of the company's Q1 results on April 27. Tenthoff models for $14M of Exondys51 sales in the quarter.
04/26/17
JANY
04/26/17
NO CHANGE
Target $65
JANY
Buy
Janney sees Sarepta selling off without material guidance raise
Going into tomorrow's earnings report from Sarepta Therapeutics, the Street is expecting a significant increase to FY17 guidance, which may not materialize, Janney Capital analyst Debjit Chattopadhyay tells investors in a pre-earnings research note. The FY17 consensus estimate for Exondys51 sales is $96M versus management's guidance of $80M-plus, the analyst points out. Chattopadhyay believes Sarepta shares could be pressured if guidance is not materially higher than the consensus since the stock is up $7 since April 11. The analyst continues to like Sarepta's intermediate to long-term outlook and recommends buying the shares on any meaningful pullbacks. Chattopadhyay has a Buy rating on the shares with a $65 fair value estimate. Sarepta in morning trading is down 58c to $35.23.
04/28/17
LEER
04/28/17
NO CHANGE
Target $52
LEER
Outperform
Sarepta price target raised to $52 from $47 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Sarepta to $52 from $47 after the company reported $16.3M in Exondys51 sales in Q1 that beat estimates and easily surpassed the company's guidance. The analyst reiterates an Outperform rating on the shares.
05/12/17
PIPR
05/12/17
NO CHANGE
Target $43
PIPR
Overweight
Sarepta panel should not impact planned interim analysis, says Piper Jaffray
After the FDA posted briefing documents ahead of a joint meeting on May 18 to vote on a parent's request for the inclusion of alternative venous access device in Sarepta's Phase III ESSENCE study of SRP-4045 and SRP-4053, Piper Jaffray analyst Edward Tenthoff said the decision should not impact the planned interim efficacy analysis after 48-week data are available, but a "Yes" vote would be beneficial for DMD boys and potentially lower discontinuation rates. He maintains his $43 price target and Overweight rating on Sarepta shares.

TODAY'S FREE FLY STORIES

SPLS

Staples

$8.78

0.1 (1.15%)

10:27
05/25/17
05/25
10:27
05/25/17
10:27
Periodicals
Breaking Periodicals news story on Staples »

Staples rejected Cerberus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.38

0.365 (0.70%)

10:25
05/25/17
05/25
10:25
05/25/17
10:25
Options
Nike call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBIO

KaloBios

$2.20

-0.05 (-2.22%)

10:20
05/25/17
05/25
10:20
05/25/17
10:20
Hot Stocks
KaloBios comments on publication reporting higher death risk with Chagas »

KaloBios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
05/25/17
05/25
10:20
05/25/17
10:20
General news
Today's U.S. reports »

Today's U.S. reports…

$NSD

NASDAQ Market Internals

10:17
05/25/17
05/25
10:17
05/25/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$7.47

-0.31 (-3.98%)

, AMZN

Amazon.com

$980.35

8.81 (0.91%)

10:16
05/25/17
05/25
10:16
05/25/17
10:16
Hot Stocks
Sears soars after reporting smaller than expected quarterly loss »

Shares of Sears Holdings…

SHLD

Sears

$7.47

-0.31 (-3.98%)

AMZN

Amazon.com

$980.35

8.81 (0.91%)

JCP

J.C. Penney

$4.74

0.085 (1.83%)

M

Macy's

$23.60

0.4196 (1.81%)

TGT

Target

$54.26

0.13 (0.24%)

STWD

Starwood Property

$22.19

0.05 (0.23%)

KSS

Kohl's

$38.62

0.6899 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 01

    Jun

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

$NYE

NYSE Market Internals

10:16
05/25/17
05/25
10:16
05/25/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
05/25/17
05/25
10:15
05/25/17
10:15
General news
Breaking General news story  »

Week of 5/19 EIA Natural…

CSRA

CSRA

$31.08

1.44 (4.86%)

10:12
05/25/17
05/25
10:12
05/25/17
10:12
Hot Stocks
CSRA unit wins five-year $266M EPA contract »

CSRA announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 01

    Jun

  • 02

    Jun

TWLO

Twilio

$25.10

-0.95 (-3.65%)

, ZEN

Zendesk

$25.86

0.02 (0.08%)

10:07
05/25/17
05/25
10:07
05/25/17
10:07
Recommendations
Twilio lower after Northland details relationship with Airbnb »

Airbnb, which currently…

TWLO

Twilio

$25.10

-0.95 (-3.65%)

ZEN

Zendesk

$25.86

0.02 (0.08%)

VG

Vonage

$6.94

0.025 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 08

    Jun

  • 08

    Jun

SITO

SITO Mobile

$4.16

-0.05 (-1.19%)

10:06
05/25/17
05/25
10:06
05/25/17
10:06
Downgrade
SITO Mobile rating change  »

SITO Mobile downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESE

ESCO Technologies

$57.65

-0.2 (-0.35%)

10:02
05/25/17
05/25
10:02
05/25/17
10:02
Hot Stocks
ESCO Technologies acquires assets of Morgan Schaffer, terms not disclosed »

ESCO Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

ALXN

Alexion

$101.08

-3.56 (-3.40%)

10:00
05/25/17
05/25
10:00
05/25/17
10:00
Upgrade
Alexion rating change  »

Alexion upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

XLNX

Xilinx

$64.44

0.47 (0.73%)

10:00
05/25/17
05/25
10:00
05/25/17
10:00
Options
Bullish option play in Xilinx as shares advance »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

09:56
05/25/17
05/25
09:56
05/25/17
09:56
Conference/Events
Jefferies financial/banks analysts hold an analyst/industry conference call »

Analysts discuss trust…

09:55
05/25/17
05/25
09:55
05/25/17
09:55
General news
Bloomberg Consumer Comfort Index Level data reported »

Week of 5/21 Bloomberg…

BBD

Banco Bradesco

$8.46

0.025 (0.30%)

09:55
05/25/17
05/25
09:55
05/25/17
09:55
Options
Banco Bradesco put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$56.94

6.52 (12.93%)

, PVH

PVH Corp.

$106.53

4.49 (4.40%)

09:55
05/25/17
05/25
09:55
05/25/17
09:55
Options
Early notable gainers among liquid option names on May 25th »

Notable gainers among…

BBY

Best Buy

$56.94

6.52 (12.93%)

PVH

PVH Corp.

$106.53

4.49 (4.40%)

CSRA

CSRA

$30.51

0.87 (2.94%)

ADS

Alliance Data

$247.05

9.335 (3.93%)

NFLX

Netflix

$157.75

-0.2 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 25

    May

  • 25

    May

  • 31

    May

  • 31

    May

  • 01

    Jun

  • 01

    Jun

  • 02

    Jun

  • 05

    Jun

  • 13

    Jun

09:55
05/25/17
05/25
09:55
05/25/17
09:55
General news
Fed policy outlook: Fed funds futures are little changed to slightly firmer »

Fed policy outlook: Fed…

WOW

WideOpenWest

09:54
05/25/17
05/25
09:54
05/25/17
09:54
Syndicate
Breaking Syndicate news story on WideOpenWest »

WideOpenWest opens for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

NFLX

Netflix

$157.75

-0.2 (-0.13%)

09:54
05/25/17
05/25
09:54
05/25/17
09:54
Conference/Events
William Blair Internet/Media analyst holds an analyst/industry conference call »

Media/Internet Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 05

    Jun

PM

Philip Morris

$118.01

0.58 (0.49%)

09:52
05/25/17
05/25
09:52
05/25/17
09:52
Hot Stocks
FDA begins scientific review of Philip Morris MRTP application for EHTP »

On May 24, the US FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$32.50

0.85 (2.69%)

09:50
05/25/17
05/25
09:50
05/25/17
09:50
Downgrade
Triumph Group rating change  »

Triumph Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:50
05/25/17
05/25
09:50
05/25/17
09:50
Hot Stocks
Breaking Hot Stocks news story  »

Reading International…

TGI

Triumph Group

$32.00

0.35 (1.11%)

09:47
05/25/17
05/25
09:47
05/25/17
09:47
Downgrade
Triumph Group rating change  »

Triumph Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.